Screener
Veracyte VCYT Testing revenue — Compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept vcyt:CostOfRevenueCompensationExpense.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cost of testing revenue: | ||
| Laboratory supplies and reagents expense | 12,314 | 13,067 |
| Sample collection expense | 3,288 | 2,825 |
| Compensation expense | 9,804 | 5,611 |
| Other cost of testing revenue (1) | 4,937 | 3,385 |
| Allocation of facilities and IT expenses | 2,963 | 3,372 |
| Total cost of testing revenue | 33,306 | 28,260 |
| Cost of product revenue: |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's testing revenue — compensation expense?
- Veracyte (VCYT) reported testing revenue — compensation expense of $9.8M in Q1 2026.
- How has Veracyte's testing revenue — compensation expense changed year-over-year?
- Veracyte's testing revenue — compensation expense increased by 74.7% year-over-year, from $5.61M to $9.8M.
- What is the long-term trend for Veracyte's testing revenue — compensation expense?
- Over 3 years (2022 to 2025), Veracyte's testing revenue — compensation expense has grown at a 13.1% compound annual growth rate (CAGR), from $17.02M to $24.61M.
- What does testing revenue — compensation expense mean?
- This represents the direct personnel costs, including salaries and benefits, for staff specifically dedicated to the laboratory testing and diagnostic operations. It provides insight into the labor intensity required to maintain testing throughput.
Ask your AI about Veracyte's testing revenue — compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude